Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild‐type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF
1. Gilead Sciences, Inc., Foster City, California;2. Toronto General Hospital, Toronto, Ontario, Canada;3. New Zealand Liver Transplant Unit, Auckland, New Zealand